MedTrace Logo

Abemaciclib in Metastatic or Locally Advanced Anaplastic/Undifferentiated Thyroid Cancer

NCT04552769 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2025-06-05

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the efficacy of treatment with abemaciclib in patients with anaplastic thyroid/undifferentiated thyroid

Conditions

  • Thyroid Cancer
  • Anaplastic Thyroid Cancer
  • Undifferentiated Thyroid Cancer

Interventions

DRUG

Abemaciclib

200 mg orally

Sponsors & Collaborators

Principal Investigators

  • Saad A Khan, MD · Stanford Universiy

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-09-10
Primary Completion
2023-04-12
Completion
2025-01-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04552769 on ClinicalTrials.gov